ADRM1 and Miyoshi myopathy: Moreover, blocking the UPR cascade induces immunogenic cell death (ICD) (e.g., by bortezomib the type 1 IFN signature) via calreticulin expression (“eat-me-signal”) and the cGAS/STING pathway activation [129,130], whilst targeting Rpn13 in dendritic cells triggers T and NK cell anti-MM immunity [131].